4D Molecular Therapeutics Inc logo

4D Molecular Therapeutics Inc

FDMT
Healthcare|Biotechnology|USA
$12.30
-0.58 (-4.50%)
Tangible Book
$8.64

Upcoming Data Readouts (6)

Mar 2027
Est. completion
P1P2Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270n=215
May 2027
Est. completion
P1Choroideremia
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
NCT04483440n=13
Jun 2027
Est. completion
P2Cystic Fibrosis Lung
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230n=30
Jun 2027
Est. completion
P3Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988n=480
Nov 2028
Est. completion
P3Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759n=480
Feb 2029
Est. completion
P2Diabetic Macular Edema
4D-150 in Patients With Diabetic Macular Edema
NCT05930561n=72

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P1P2
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCT04517149
Jan 2026
P1P2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
NCT04519749

Recent Press Releases